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Background/aim: QF-PCR has been used for more than 20 years. It is based on investigation of polymorphic short tandem repeats
(STRs) and is widely used for prenatal rapid aneuploidy detection.
Materials and methods: We report retrospectively our prenatal diagnosis results between January 2012 and May 2014 in Tepecik
Training and Research Hospital Genetic Diagnostic Center. Prenatal diagnosis was recommended in 6800 high-risk pregnancies and
2883 patients agreed to invasive diagnosis. Chromosome analysis and QF-PCR were performed in all patients.
Results: Normal results were reported in 2711 cases by fetal karyotyping and in 2706 cases by QF-PCR. Anomaly detection rates were
similar for the two methods (5.09% for karyotyping and 4.02% for QF-PCR).
Conclusion: QF-PCR is a fast and reliable prenatal diagnosis method in all indication groups and may be preferred as the sole prenatal
investigation in patients without fetal ultrasonographic findings.
Key words: Amniocentesis, chromosome aberrations, prenatal diagnosis, genetic counseling, polymorphism

1. Introduction
Several invasive techniques are used to detect fetal
chromosome anomalies during the prenatal period.
Until quite recently, conventional chromosome analysis
of fetal samples was regarded as the gold standard for
prenatal diagnosis. However, currently, for fetuses with
ultrasonographic findings, cytogenetic microarray (CMA)
analysis is recommended for preliminary investigations
and for fetuses with other risk factors, QF-PCR analysis
(1). As is the case in many other countries, conventional
cytogenetic analysis is still the major diagnostic approach
in this country. The main disadvantage of the conventional
approach is the prolonged duration of reporting time
due to long-term cell cultures. Although international
guidelines suggest 2 weeks reporting time for prenatal
tests (2), the actual duration of fetal karyotyping is around
3–4 weeks, especially in centers with high numbers of
samples. As another disadvantage, karyotyping may give
unexpected findings other than aneuploidies. The reports
may increase the patient’s anxiety due to uncertain clinical
outcome. The diagnostic investigation may even end with
unnecessary termination of the pregnancy.
Advanced maternal age and increased aneuploidy risk
in maternal serum screening were reported as the major
* Correspondence: drozgeozer@gmail.com
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indications for prenatal cytogenetic diagnosis (3), and
these indications aim to identify aneuploidies mainly.
Thus, the rapid aneuploidy detection (RAD) methods
are included in daily practice (4). Fluorescence in situ
hybridization (FISH) was used for rapid detection initially.
Direct examination of uncultured interphase cells is the
major advantage of FISH but the relatively expensive and
laborious procedures limit the use of rapid FISH (5).
QF-PCR has been used for more than 20 years
(6). It is based on investigation of polymorphic short
tandem repeats (STRs) and is used widely for prenatal
rapid aneuploidy detection. Determination of trisomic
aneuploidy is based on amplification of STRs. Each
specific STR has a specific length according to the
number of repeats, thus distinguishing one homologous
chromosome from its counterpart is possible. In contrast
to fetal karyotyping, QF-PCR can be carried out with very
low quantities of samples in remarkably shorter periods of
time. Worldwide patient series are reported for QF-PCR
(1,7–9), but STR marker variations among populations
lead to the necessity of population-based reports. In the
present study, we report our QF-PCR experience and the
informativeness of STR markers for a Turkish population.
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2. Materials and methods
Samples were collected between January 2012 and May
2014 in Tepecik Training and Research Hospital Genetic
Diagnostic Center. All patients were offered genetic
counseling before the invasive procedure. All of the
patients were informed about the procedures, limitations,
possible results, and complications. Informed consent was
obtained in all cases. Increased aneuploidy risks in maternal
serum screening, presence of ≥2 soft markers or major
malformation on fetal ultrasonography, and advanced
maternal age (≥35 years at birth) were the indications
for prenatal invasive diagnosis. Patients with incomplete
clinical data were not included in the study.
Prenatal diagnosis was recommended for 6800 highrisk pregnancies and 2883 (42%) patients agreed to
invasive diagnosis. Chromosome analysis and QF-PCR
was performed for all patients. The majority (84%) of the
patients (n: 2427) underwent amniocentesis (AC), 12%
(n: 333) chorionic villi sampling (CVS), and 4% (n: 123)
cordocentesis (CS).
Chromosome analysis was performed according to
conventional methods. Short- and long-term cell cultures
were used for appropriate samples; direct karyotyping was
not used.
2.1. QF-PCR
Genomic DNA was isolated from a 2-mL amniotic
fluid sample, 200-µL fetal blood sample, or 40–60mg chorionic villous sample using a High Pure PCR
Template Preparation Kit (Roche, USA) according to the
manufacturer’s instructions. Discolored amniotic fluid
samples (suggested having maternal blood contamination),
fetal cord blood samples, and chorionic villi samples were
also compared with maternal peripheral blood samples
to exclude maternal cell contamination. QF-PCR assays
were performed with a commercially available Devyser
Complete QF-PCR kit Version 1 (Devyser, Sweden). At
least 7 STR markers for each 3 autosomal (13, 18, 21) and
2 sex (X, Y) chromosomes were analyzed, and 50-ng/µL
DNA samples were used per PCR mix. PCR was performed
in 25-µL total volume. PCR conditions were as follows: first
denaturation at 95 °C for 15 min, 26 cycles for denaturation
at 94 °C for 30 s, annealing at 58 °C for 90 s, extension at 72
°C for 90 s, and final extension at 72 °C for 30 min.

Eight microliters of PCR products were mixed with
10 µL of formamide and 0.5 µL of ROX size standard
(ABI, USA) in a MicroAmp (Applied Biosystems, USA)
optical 96-well reaction plate. After being denatured for
3 min at 95 °C and cooled for 3 min at –20 °C, capillary
electrophoresis was performed in an ABI 3130 system
(ABI, USA). The GeneScan Analysis program was used for
determination of peak length and areas.
2.2. Data interpretation
The results were defined according to peak areas and
described as 1:1, 1:1:1, 2:1, or uninformative (when there
was only one peak). The allele dosage ratio interpretation
criteria are summarized in Table 1 for informative
markers. At least two informative markers were chosen
to give normal results for each chromosome and at least
3 markers were needed to report an anomaly. Extra
markers were used for confirmation of uninformative
results. When a trisomic pattern (2:1 or 1:1:1 ratios) was
detected in only one marker, parental samples were tested
to exclude a partial duplication. The study was repeated at
DNA isolation level in the case of amplification failure at
least twice.
Heterozygosity ratios were evaluated for 22 STR
markers in 605 objects that were randomly selected from
the patient group. X1, X2, X3, Y1, and 7X markers are not
shown in the heterozygosity results table. Patients with
numerical chromosome abnormalities were excluded
from the interpretation.
3. Results
The most common indication for chromosome analysis
was an abnormal maternal serum screening test result
(n: 1320, 45.8%). The other frequent indications were
advanced maternal age (n: 888, 30.8%) and abnormal
fetal ultrasound findings (n: 593, 20.6%). Relatively rare
indications were maternal anxiety, Down syndrome history
in early pregnancies, and familial reciprocal translocation
(n: 82, 2.8%).
Chromosome analysis and QF-PCR results are shown
in Table 2. Normal results were reported in 2711 cases
(94.03%) by fetal karyotyping and in 2706 cases (93.86%)
by QF-PCR. Anomaly detection rates were similar for the
two methods (5.09% for karyotyping and 4.02% for QF-

Table 1. Allele dosage ratio interpretation criteria.
Result

Allele dosage ratio
Two peak distance <25 bp

Two peak distance >25 bp

Normal

<1.45

<1.52

Gray zone

1.45–1.80

1.52–1.80

Trisomy

≥1.80

≥1.80
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Table 2. Genetic anomaly rates in fetal cytogenetic analysis and QF-PCR.

Trisomy 21

Karyotype

%

QF-PCR

%

60

2.08

58

2.01

Trisomy 13

5

0.17

7

0.24

Trisomy 18

28

0.97

28

0.97

Monosomy X

13

0.45

13

0.45

Other mosaic aneuploidies*

4

0.14

0

0.00

Mosaic trisomy 13

1

0.03

0

0.00

45,X/46,XX

1

0.03

0

0.00

45,X/46,X,+mar/46,XX

1

0.03

0

0.00

Trisomy 22

1

0.03

0

0.00

Triploidy

3

0.10

3

0.10

XX/XY mosaicism

2

0.07

0

0.00

XXX

2

0.07

2

0.07

XXY

5

0.17

5

0.17

Balanced rearrangement

16

0.55

0

0.00

Unbalanced rearrangement

5

0.17

1

0.03

Culture or amplification failure

25

0.87

4

0.14

Uninformative results for one or more chromosome

-

-

20

0.69

Maternal cell contamination

0

0.00

37

1.28

Normal

2711

94.03

2706

93.86

TOTAL ANOMALY

147

5.10

116

4.02

* Mosaic aneuploidies other than 13, 18, 21, X, and Y.

PCR). No false positive results were observed for either
method.
Maternal cell contamination (MCC) was detected by
QF-PCR in 37 cases and the detection rate was highest in
the CVS group (11 of 333 cases, 8%). The material type
and result comparison is shown in Table 3 for the MCC
group.
QF-PCR failed due to detection of only one informative
marker, maternal cell contamination, or amplification
failure in 61 cases (2.11%) (Table 2). In total, 20 samples
had just one informative marker for sex chromosomes
(n: 9, one of them was mosaic 45,X), chromosome 21 (n:
6), chromosome 18 (n: 2), chromosome 13 (n: 2), and for
both chromosomes 18 and 21 (n: 1). Culture failure was
seen in 0.91% of fetal karyotyping studies.
Discordant results among QF-PCR and fetal
karyotyping are summarized in Tables 4 and 5.
Among the 111 cases with nonmosaic numerical
chromosomal abnormalities detected by fetal karyotyping,
three of them were not detected by QF-PCR. The detection
failure in this group by QF-PCR was due to amplification
failure and maternal contamination for two of the cases.
For one of them, the case was monosomy X could not be
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analyzed because of an inadequate number of informative
sex chromosome makers.
Heterozygosity ratios are shown in Table 6 with STR
locus for markers. Polymorphic aberrations (2:1 or 1:1:1
ratio for one marker) were observed in D21S11, D13S634,
D13S742, D13S628, D21S1412, and D21S1446 markers;
almost all of them were inherited parentally and seemed
to be benign.
Table 3. Comparison of QF-PCR results between different sample types MCC group.
AC

CVS

CS

45,X/46,X,+mar/46,XX

1

-

-

46,XX/46,XY

1

-

1

Normal

20

7

-

Trisomy 21

1

-

-

Culture failure

1

4

1

AC: Amniocentesis, CVS: Chorion villus sample, CS: Cordocentesis.
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Table 4. Discordance results and testing indications.
Abnormal maternal serum
screening test results

AMA

Abnormal fetal
ultrasound findings

Family history

Balanced (apparently) rearrangement

8

3

2

3

Unbalanced rearrangement

2

1

1

0

Unbalanced numerical abnormality

1

3

3

0

AMA: Advanced maternal age.
Table 5. Number of abnormalities detected by one method but not the other.
Chromosomal abnormality

Number of patients (%)

Failed method

Comment

Trisomy 21

2 (0.07)

QF-PCR

One amplification failure and one MCC

Trisomy 13

2 (0.07)

Chromosome analysis

Culture insufficiency

Other mosaic aneuploidies*

4 (0.14)

QF-PCR

No marker for related regions

Mosaic trisomy 13

1 (0.03)

QF-PCR

Possible low level mosaicism

45,X/46,XX

1 (0.03)

QF-PCR

MCC

45,X/46,X,+mar/46,XX

1 (0.03)

QF-PCR

Uninformative markers for sex chromosomes

Trisomy 22

1(0.03)

QF-PCR

No marker for related regions

XX/XY mosaicism

2 (0.07)

QF-PCR

MCC

Balanced rearrangement

16 (0.55)

QF-PCR

Out of detection capability

Unbalanced rearrangement

4 (0.14)

QF-PCR

No marker for related regions

4. Discussion
QF-PCR is a routine diagnostic tool for screening frequent
chromosomal aneuploidies. Previously, researchers have
suggested that it is a fast, cheap, and reliable diagnostic
method (10–12). In our population, QF-PCR is widely
used but no large series were reported to date (13).
In our daily routine, sole advanced maternal age is still
a frequent indication of prenatal diagnosis. In previous
reports, the main indication for prenatal diagnosis was
advanced maternal age (≥35 years); in contrast to those
reports we showed that increased aneuploidy risk in
maternal serum screening is the major invasive prenatal
test indication (3). Efficient use of first trimester maternal
serum screening combined with fetal nuchal translucency
measurement is the reason for the distinct indication
frequencies among previous and recent studies.
The aneuploidy detection capability of QF-PCR is
determined according to 3 factors: test failure, false
positive, and false negative rates (14). QF-PCR failure was
reported as 1.3% due to maternal cell contamination and
the failure ratio for conventional cell culture (karyotyping)
was 0.12%–0.3% (14). In our study the MCC rate was
similar: 1.28%. Most of the MCC was detected in the
CVS group. Seven patients with MCC were detected by
QF-PCR, although they were reported as normal by fetal

karyotyping. Therefore, genetic counseling about MCC
rates is obviously needed for fetal karyotyping by CVS.
In our study, just 4 cases (0.14%) could not be reported
by QF-PCR due to amplification failure. In contrast, 25
(0.87%) cases were not reported by fetal karyotyping due to
culture failure. QF-PCR has lower failure rates.
Previously, in the literature, it was underlined that the
main factor for evaluation of QF-PCR performance was
number of STR markers (14). In our study, 7 markers are
used for each chromosome (13, 18, 21, X, Y). Compatible
with previous reports (7,10,13), we had no false positive
results.
Mosaic cases are important for the management of
pregnancy in clinical practice. Low level mosaicism may
not be detected by molecular methods. In our study mosaic
trisomy 13, 45,X/46,XX, and 45,X/46,X,+mar/46,XX
karyotypes were detected by chromosome analysis in 3 cases
but not by QF-PCR. Analysis reports should be prepared
carefully for such situations and pretest genetic counseling
should include mosaicism risk.
QF-PCR is used as a stand-alone test for selected
indications in United Kingdom (15). It has been accepted
that merely QF-PCR could be an efficient method for
screening chromosome aneuploidies for referrals without
fetal ultrasound findings. Distinct opinions about this issue
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Table 6. Heterozygosity ratios of STR markers used in QF-PCR study.
Marker ID

STR LOCUS

Informative

Uninformative

Heterozygosity (%)

13A
13B
13C
13D
13E
13F
13G
18A
18B
18C
18D
18G
18J
18M
21A
21B
21C
21D
21E
21F
21G
XY2

D13S742
D13S634
D13S628
D13S305
D13S800
D13S252
D13S325
D18S391
D18S978
D18S535
D18S386
D18S976
D18S976
GATA178F11
D21S1435
D21S11
D21S1411
D21S1444
D21S2039
D21S1412
D21S1446
DXYS267

556
526
440
497
443
465
460
388
439
476
552
455
453
508
468
492
528
459
450
501
448
475

48
76
156
101
157
136
142
215
164
129
48
147
145
95
128
104
76
139
134
100
146
126

92.05
87.38
73.83
83.11
73.83
77.37
76.41
64.34
72.8
78.68
92
75.58
75.75
84.25
78.52
82.55
87.42
76.76
77.05
83.36
75.42
79.03

are present (16). In our study, just one case seems to be missed
if we used QF-PCR solely in fetuses without ultrasound
findings. Therefore, we suggest that it is convenient to use
QF-PCR as a stand-alone test in this group.
Polymorphic STR duplications have been discussed
before and assessment of parental samples has been suggested
to exclude partial trisomies (7). In our study, a polymorphic
trisomic pattern was observed in 24 cases (data not shown).
All of these results were confirmed with parental studies
and accepted as normal variant or polymorphic changes.
Commercially available STR markers or QF-PCR kits are
used for routine testing. Nevertheless these polymorphic
markers could be specific for each population. Therefore,
we present heterozygosity ratios for our population. These

findings will be helpful for future studies or diagnostic
applications in Turkish populations.
From an ethical perspective, it has been speculated that
patients should choose their prenatal diagnosis method
(17). As an alternative approach, we suggest that QF-PCR
may be recommended to all indication groups at first, and
patients with normal QF-PCR results and fetal anomaly
may undergo CMA analysis as the second step of the
prenatal investigation.
The presented report is an example of a routine prenatal
diagnostic work-up in Turkey. In conclusion, it is obvious
to regard QF-PCR as a fast and reliable prenatal diagnosis
method in all indication groups and it may be used as
the sole prenatal investigation in patients without fetal
ultrasonographic findings.
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